(RS)-KETOPROFEN
PONV
IVO JURISICSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
8 Active assets in the PONV cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
RAMIFENTANYL IVO JURISIC | N/A | D |
Granisetron IVO JURISIC | N/A | D |
Meperidine IVO JURISIC | N/A | D |
NEPENTHE IVO JURISIC | N/A | D |
FENTANYL IVO JURISIC | N/A | D |
(±)-TRAMADOL IVO JURISIC | N/A | D |
DEXAMETHASONE IVO JURISIC | N/A | D |
S-Ketamine IVO JURISIC | N/A | D |
Same molecule, other indications
(RS)-KETOPROFEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →